Novartis Buys Neuroscience Company, Cadent, For Up To $770 Million
Novartis said on Thursday it would acquire U.S.-based neuroscience company Cadent for up to $770 million, gaining full rights to Cadent’s portfolio.
“Cadent will receive a $210 million upfront payment and will be eligible for up to $560…